Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Kyverna Therapeutics, Inc. ( (KYTX) ) just unveiled an announcement.
On October 31, 2025, Kyverna Therapeutics secured a loan facility of up to $150 million from Oxford Finance LLC, enhancing its financial flexibility to support its clinical programs. The company plans to draw an initial $25 million on November 3, 2025, to advance its late-stage indications and pre-launch activities, with topline data from its Phase 2 trial for stiff person syndrome expected in early 2026.
The most recent analyst rating on (KYTX) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Underperform.
Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company’s technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock’s performance.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development for conditions such as stiff person syndrome and myasthenia gravis.
Average Trading Volume: 563,882
Technical Sentiment Signal: Buy
Current Market Cap: $301.4M
See more insights into KYTX stock on TipRanks’ Stock Analysis page.